A clinical study of CS1002 a CTLA-4 inhibitor for Cancer.

Trial Profile

A clinical study of CS1002 a CTLA-4 inhibitor for Cancer.

Planning
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs CS-1002 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jan 2018 New trial record
    • 29 Dec 2017 According to a CStone Pharmaceuticals media release, an investigational new drug (IND) filing has been submitted to Human Research Ethics Committees of the Ashford Cancer Center in Australia for CS1002.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top